468 related articles for article (PubMed ID: 31005167)
21. Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.
Zhao B; Yao J; Wang J; Li J; Shi W; Zhang C; Zhao X; Qiao J; Ma Y; Xu Y; Zheng Z
Neurol Sci; 2024 Jun; 45(6):2845-2851. PubMed ID: 38228940
[TBL] [Abstract][Full Text] [Related]
22. MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered.
Zhao JP; Liu XJ; Lin HZ; Cui CX; Yue YJ; Gao S; Xu HZ
BMC Neurol; 2022 Dec; 22(1):498. PubMed ID: 36550486
[TBL] [Abstract][Full Text] [Related]
23. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of apparent diffusion coefficient in differentiating between high-grade gliomas and brain metastases.
Caravan I; Ciortea CA; Contis A; Lebovici A
Acta Radiol; 2018 May; 59(5):599-605. PubMed ID: 28835111
[TBL] [Abstract][Full Text] [Related]
25. Tectal Low-Grade Glioma with H3 K27M Mutation.
Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
[TBL] [Abstract][Full Text] [Related]
26. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.
Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S
AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348
[TBL] [Abstract][Full Text] [Related]
27. Machine Learning-Based Multiparametric Magnetic Resonance Imaging Radiomics for Prediction of H3K27M Mutation in Midline Gliomas.
Kandemirli SG; Kocak B; Naganawa S; Ozturk K; Yip SSF; Chopra S; Rivetti L; Aldine AS; Jones K; Cayci Z; Moritani T; Sato TS
World Neurosurg; 2021 Jul; 151():e78-e85. PubMed ID: 33819703
[TBL] [Abstract][Full Text] [Related]
28. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
29. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
30. Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures.
Banan R; Akbarian A; Samii M; Samii A; Bertalanffy H; Lehmann U; Hartmann C; Brüning R
PLoS One; 2021; 16(8):e0249647. PubMed ID: 34347774
[TBL] [Abstract][Full Text] [Related]
31. Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas.
Su CQ; Lu SS; Zhou MD; Shen H; Shi HB; Hong XN
Clin Radiol; 2019 Feb; 74(2):154-160. PubMed ID: 30391048
[TBL] [Abstract][Full Text] [Related]
32. Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas.
Raab P; Banan R; Akbarian A; Esmaeilzadeh M; Samii M; Samii A; Bertalanffy H; Lehmann U; Krauss JK; Lanfermann H; Hartmann C; Brüning R
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326549
[TBL] [Abstract][Full Text] [Related]
33. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
34. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
Low JT; Wang SH; B Peters K
CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
[TBL] [Abstract][Full Text] [Related]
35. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y
J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging.
Liu S; Zhang Y; Kong Z; Jiang C; Wang Y; Zhao D; You H; Ma W; Feng F
BMC Neurosci; 2022 Dec; 23(1):72. PubMed ID: 36471242
[TBL] [Abstract][Full Text] [Related]
37. An adult case of diffuse midline glioma with H3 K27M mutation.
Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
[TBL] [Abstract][Full Text] [Related]
38. Preoperative grading of supratentorial gliomas using high or standard b-value diffusion-weighted MR imaging at 3T.
Cihangiroglu MM; Ozturk-Isik E; Firat Z; Kilickesmez O; Ulug AM; Ture U
Diagn Interv Imaging; 2017 Mar; 98(3):261-268. PubMed ID: 28038915
[TBL] [Abstract][Full Text] [Related]
39. Grading Gliomas Capability: Comparison between Visual Assessment and Apparent Diffusion Coefficient (ADC) Value Measurement on Diffusion-Weighted Imaging (DWI).
Phuttharak W; Thammaroj J; Wara-Asawapati S; Panpeng K
Asian Pac J Cancer Prev; 2020 Feb; 21(2):385-390. PubMed ID: 32102515
[TBL] [Abstract][Full Text] [Related]
40. Diffuse midline glioma with H3 K27M mutation of the spinal cord: A series of 33 cases.
Yao J; Wang L; Ge H; Yin H; Piao Y
Neuropathology; 2021 Jun; 41(3):183-190. PubMed ID: 33599007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
